Valneva SE
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $VALN in the last 30 days.
See all $VALN insider activity →Pfizer and Valneva's Lyme disease vaccine, LB6V, showed 73.2% efficacy in a phase 3 trial but missed its primary endpoint. The vaccine targets six common serotypes of B. burgdorferi. The trial involved nearly 10,000 participants. Lyme disease affects around 476,000 people annually in the U.S. according to the CDC.
The UK's MHRA revoked Valneva's Ixchiq chikungunya vaccine approval, citing safety concerns. Valneva disagrees but won't appeal. Bavarian Nordic's Vimkunya is now the only approved vaccine in the UK. Valneva shares were unchanged, while Bavarian Nordic's rose 0.5%.
Valneva SE (VALN) announced the UK revoked marketing authorization for its chikungunya vaccine, IXCHIQ, after a safety review. The decision, not tied to new safety concerns, does not affect IXCHIQ's approval in other regions. Valneva stated minimal financial impact and no plans to appeal, focusing on markets with higher chikungunya risk.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning VALN (Valneva SE). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent VALN coverage spans regulation, earnings and technology.
Valneva faces similar market uncertainty as Pfizer; the data may delay its commercial rollout plans.
The UK's MHRA revoked Valneva's Ixchiq chikungunya vaccine approval, citing safety concerns. Valneva disagrees but won't appeal. Bavarian Nordic's Vimkunya is now the only approved vaccine in the UK. Valneva shares were unchanged, while Bavarian Nordic's rose 0.5%.
The revocation removes the only remaining UK market for IXCHIQ, likely reducing Valneva's revenue and prompting a sell‑off.
The stock is under pressure as technical support has been breached, suggesting further downside.
Significant upside potential for Valneva if approval is achieved, given its small size and limited coverage.
AlphAI scores every news story that mentions VALN with an AI model for sentiment and relevance, and aggregates insider trades from Valneva SE's SEC EDGAR Form 4 filings. Figures refresh continuously.
Pfizer and Valneva's Lyme disease vaccine, LB6V, showed 73.2% efficacy in a phase 3 trial but missed its primary endpoint. The vaccine targets six common serotypes of B. burgdorferi. The trial involved nearly 10,000 participants. Lyme disease affects around 476,000 people annually in the U.S. according to the CDC.
2 min readThe UK's MHRA revoked Valneva's Ixchiq chikungunya vaccine approval, citing safety concerns. Valneva disagrees but won't appeal. Bavarian Nordic's Vimkunya is now the only approved vaccine in the UK. Valneva shares were unchanged, while Bavarian Nordic's rose 0.5%.
2 min readValneva SE (VALN) announced the UK revoked marketing authorization for its chikungunya vaccine, IXCHIQ, after a safety review. The decision, not tied to new safety concerns, does not affect IXCHIQ's approval in other regions. Valneva stated minimal financial impact and no plans to appeal, focusing on markets with higher chikungunya risk.
2 min readValneva's stock fell 2.53% to €2.55, breaking support at €2.61 and underperforming the SBF 120 index. It is below key moving averages, with the MA200 at €3.08, 17.37% above current price. The company confirmed 2026 guidance despite geopolitical impacts on travel vaccine sales, expecting improved margins in H2.
1 min readPfizer (PFE) and Valneva (VALN) announced the EMA has started reviewing their Lyme disease vaccine candidate, PF-07307405, based on Phase 3 trial data showing over 70% efficacy. The trial met one statistical criterion but not the primary endpoint. Pfizer will commercialize the vaccine if approved, while Valneva benefits as a development partner.
3 min readValneva (VALN) reported H1 2026 results with €64M in product sales, a net loss of €63.3M, and reaffirmed 2026 guidance. Sales declines were driven by reduced distribution activities and lower travel vaccine demand. The company is focusing on cash preservation and expects regulatory decisions for its Lyme disease vaccine candidate within 12 months, according to management.
3 min readValneva (VALN) reported H1 2026 results: €64M product sales, €63.3M net loss, and €121.5M cash. Sales declined due to reduced distribution and lower IXIARO (€44M) and DUKORAL (€14.7M) revenues. Gross margins fell for both vaccines. The company reaffirmed 2026 guidance: €135M-€150M product sales, €145M-€160M total revenue. Pfizer expects EMA decision on Lyme disease vaccine within 12 months. Valneva is restructuring, consolidating R&D in Vienna, and focusing on cash preservation.
3 min readUS markets closed lower on Friday, with the Dow, NASDAQ, and S&P 500 falling 0.26%, 0.51%, and 0.24% respectively. Retail sales declined 0.6% in July, missing estimates, and consumer sentiment dropped to 51 in August. Energy stocks rose 1.3%, while tech fell 0.6%. Eton Pharmaceuticals (ETON) surged 39% on strong earnings, while KinderCare (KLC) fell 31% after missing expectations.
2 min readThe EMA validated Pfizer and Valneva’s marketing authorization application for their Lyme disease vaccine candidate PF-07307405 and will begin formal review. The submission relies on Phase III VALOR data from 9,437 participants, showing over 70% efficacy and no identified safety concerns, according to the companies. Pfizer holds exclusive manufacturing and commercialization rights if approved.
4 min readLyme disease cases in Canada rose from 144 in 2009 to 5,809 in 2024, with 7,105 preliminary cases for 2025, according to PHAC data. The article says no human Lyme vaccine is currently approved. Pfizer and Valneva’s PF-07307405 completed Phase 3 with over 70% efficacy after four doses, and Moderna has Phase 2 candidates mRNA-1975 and mRNA-1982.
7 min read
